Similarly to our UK cohort, 40% of JDM patients with an anti-synthetase autoantibody developed interstitial lung disease, but this increased to 100% of those with anti-Ro52 and an anti-synthetase autoantibody [23]. This evidence concerns the gene TRIM21 and interstitial lung disease.